- Conditions
- Critical Illness, Heart Failure, Sepsis, Ards, Pneumonia, Trauma Injury
- Interventions
- Lift mobile mindfulness, Enlighten Recovery education program
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Durham, North Carolina • Charleston, South Carolina
Condition Directory
Heart Failure clinical trials
Directory of U.S. ClinicalTrials.gov public records for Heart Failure. Browse Heart Failure recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 27, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2566
Shown on this page
12
Current sort
Recently updated
Condition scope
Heart Failure
Additional filters apply within this condition.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Heart Failure studies are organized in the registry
Heart failure records routinely distinguish reduced versus preserved ejection fraction — the abbreviations HFrEF and HFpEF appear directly in titles and condition fields and are the cleanest way to split the portfolio. Device and monitoring studies form a substantial share alongside drug trials.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 313–324 of 2,566 matching trials for Heart Failure.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
- Interventions
- Stopping Heart Failure Medication(s)
- Other
- Lead sponsor
- Dinesh Thavendiranathan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Boston, Massachusetts
- Conditions
- Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- Interventions
- TX000045- Dose A, TX000045- Dose B, Placebo
- Drug
- Lead sponsor
- Tectonic Therapeutic
- Industry
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
- Conditions
- MRI Scans
- Interventions
- Adenosine, Regadenoson, O-15 labeled radioactive water, MRI, PET Imaging
- Drug · Device
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Heart Failure
- Interventions
- PAC provision at hospital discharge, Control non-intervention; PAC without filter
- Other
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Heart Failure, Polygenic Score
- Interventions
- Beta blocker
- Other
- Lead sponsor
- David Lanfear
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication
- Interventions
- No screening, Regular Screening
- Other
- Lead sponsor
- University of British Columbia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Washington D.C., District of Columbia
- Conditions
- Chronic Heart Failure, CKD Stage 3
- Interventions
- AquaPass System
- Device
- Lead sponsor
- AquaPass Medical Ltd.
- Industry
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- La Jolla, California • San Francisco, California • Minneapolis, Minnesota + 5 more
- Conditions
- Acute Heart Failure, Dyspnea, Dyspnea; Cardiac
- Interventions
- Not listed
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Rehabilitation Intervention
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Heart Failure
- Interventions
- Empagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
About this Heart Failure clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Heart Failure as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Heart Failure.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Heart Failure.